Crescent Biopharma, Inc. (CBIO) Investor Relations Documents

Crescent Biopharma, Inc. (CBIO) investor relations documents from the company's IR site: 1 presentation, 39 press releases; latest deck 2026-07-29. Read in-app with summaries. First-party data.

Corporate Presentation July 2026: Crescent Biopharma is an oncology company developing I/O and ADC therapies, highlighted by a strategic partnership with Kelun-Biotech to accelerate CR-001 combinations.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-03Press releasePDF Version
2026-08-03Press releaseCrescent Biopharma Announces Grants of Inducement Awards
2026-07-30Press releasePDF Version
2026-07-30Press releaseCrescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-07-29PresentationCorporate Presentation July 2026
2026-07-23Press releasePDF Version
2026-07-23Press releaseCrescent Biopharma Announces Grants of Inducement Awards
2026-07-16Press releasePDF Version
2026-07-16Press releaseCrescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exerc
2026-07-14Press releasePDF Version
2026-07-14Press releasePDF Version
2026-07-14Press releaseJuly 14, 2026 Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
2026-07-14Press releaseJuly 14, 2026 Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
2026-06-26Press releasePDF Version
2026-06-26Press releaseCrescent Biopharma Announces Grants of Inducement Awards
2026-06-11Press releasePDF Version
2026-06-11Press releaseCrescent Biopharma Announces Grants of Inducement Awards
2026-06-02Press releasePDF Version
2026-06-02Press releaseCrescent Biopharma to Present at June Investor Conferences
2026-05-29Press releasePDF Version
2026-05-29Press releaseCrescent Biopharma Announces Grants of Inducement Awards
2026-05-21Press releasePDF Version
2026-05-21Press releaseCrescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibod
2026-05-12Press releasePDF Version
2026-05-12Press releaseCrescent Biopharma Announces Grants of Inducement Awards
2026-05-06Press releasePDF Version
2026-05-06Press releaseCrescent Biopharma to Present at May Investor Conferences
Press releaseCrescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-04-29Press releasePDF Version
2026-04-24Press releasePDF Version
2026-04-24Press releaseCrescent Biopharma Announces Grants of Inducement Awards
2026-03-27Press releasePDF Version
2026-03-27Press releaseCrescent Biopharma Announces Grants of Inducement Awards
2026-03-06Press releasePDF Version
2026-03-06Press releaseCrescent Biopharma Announces Grants of Inducement Awards
2026-02-26Press releasePDF Version
2026-02-26Press releaseCrescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
2026-02-23Press releasePDF Version
2026-02-23Press releaseCrescent Biopharma to Present at March Investor Conferences
2026-02-19Press releasePDF Version

CBIO overview · CBIO earnings · CBIO financials · CBIO KPIs · CBIO ownership · CBIO peers · CBIO filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.